Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Investor Presentation (April 2026)
34 slides from Autolus Therapeutics's investor presentation, April 2026
Slide 1: Developing Next Generation Programmed T Cell Therapies
Developing Next Generation Programmed T Cell Therapies April 2026 For Investor communication only. Not for use in Autolus.com product promotion.
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Autolus is positioned for value creation
Developing and Delivering a New Generation of T Cell Therapies Autolus is positioned for value creation Obe-cel product franchise supports multiple growth opportunities Initial Indication: Adult r/r B-ALL Pipeline expansion opportunities Strong Execution in First Year of Launch grow future commercia
Slide 4: Autolus is a leader in CAR T manufacturing & product delivery
Developing and Delivering a New Generation of T Cell Therapies Autolus is a leader in CAR T manufacturing & product delivery Executing on manufacturing and product delivery in the first year of launch: Manufacturing success rate >90% Fast, reliable and consistent product delivery No capacity l
Slide 5: AUCATZYL
AUTOLUS’ FIRST APPROVED PRODUCT AUCATZYL® A potentially best-in-class, standalone CD19 CAR T cell therapy
Slide 6: AUCATZYL now approved in US, UK and EU
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL® now approved in US, UK and EU AUCATZYL indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) • Highly active, fast off-rate CD19 CAR T therapy with a well manage
Slide 7: Strong first year of U.S. AUCATZYL launch
Developing and Delivering a New Generation of T Cell Therapies Strong first year of U.S. AUCATZYL® launch AUCATZYL Net Product Revenue 2026 Expectations Q4 2025: $23.3 Million FY 2026 Net Product Revenue: FY 2025: $74.3 Million $120-$135 million Shift to positive gross margin in 2026 based on increa
Slide 8: AUCATZYL geographic growth opportunities in ALL
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL geographic growth opportunities in ALL Expansion Conditional marketing authorization in the UK received April 2025 UK Launch Q1 2026 Successful NICE pricing and reimbursement process Nov 2025 AUCATZYL available in routine
Slide 9: We believe AUCATZYL has a unique mechanism of action
Developing and Delivering a New Generation of T Cell Therapies We believe AUCATZYL® has a unique mechanism of action Clinical data show increased activity and reduced toxicity Fast off-rate 107 Shorter half-life of interaction Other CD19 Binders Obe-cel Binder compared to binders used in other CAT19
Slide 10: AUCATZYL was approved based on results from the FELIX trial
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL was approved based on results from the FELIX trial Background FELIX Phase 1b/2 • Open-label, multinational, single-arm Phase 1b/2 trial in adult patients with R/R B-ALL1-2; largest CAR T cell therapy trial in R/R B-ALL to date (
Slide 11: FELIX trial published in New England Journal of Medicine
Developing and Delivering a New Generation of T Cell Therapies FELIX trial published in New England Journal of Medicine1 Favourable response rate and tolerability, despite challenging patient population High overall response rate with deep molecular responses Excellent tolerability profile • Durable
Slide 12: Data continue to show long term remissions in r/r adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Data continue to show long term remissions in r/r adult B-ALL At 24 months, overall survival probability was 46.0% Jae H Park et al, EHA 2025, oral presentation #S113 12
Slide 13: Duration of response: median 42.6 months at last data cut
Developing and Delivering a New Generation of T Cell Therapies Duration of response: median 42.6 months at last data cut More than half of patients still in remission at 24 months Jae H Park et al, EHA 2025, oral presentation #S113 13
Slide 14: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 15: Pipeline supports growth with multiple development opportunities
Developing and Delivering a New Generation of T Cell Therapies Pipeline supports growth with multiple development opportunities Near-Term Growth Drivers Product Indication Target Preclinical Phase 1 Phase 2/Pivotal Approved Status AUCATZYL® FDA, MHRA^ & EC Adult ALL CD19 (obe-cel) approved† obe-cel
Slide 16: Growing the obe-cel franchise commercial opportunity
Developing and Delivering a New Generation of T Cell Therapies Growing the obe-cel franchise commercial opportunity Robust clinical database and demonstrated commercial capabilities position Autolus for efficient path in new indications Graphic is illustrative, not to scale Significant ~300,0003 Mar
Slide 17: Pediatric r/r B-ALL development strategy
Developing and Delivering a New Generation of T Cell Therapies Pediatric r/r B-ALL development strategy Regenerative Medicine Advanced Therapy (RMAT) designation supports development pathway Development Rationale: CATULUS Phase 1 CATULUS Phase 2 High Unmet Medical Need • 30 patients, SAT • Kymriah a
Slide 18: CATULUS Phase 1 data support progressing into Phase 2
Developing and Delivering a New Generation of T Cell Therapies CATULUS Phase 1 data support progressing into Phase 2 Safety profile of obe-cel in pediatric patients consistent with that previously reported in adults *One patient experienced both Grade 3 CRS and Grade 3 ICANS. ‡Time to onset (days) =
Slide 19: CATULUS data demonstrate promising initial efficacy in pediatric patients
Developing and Delivering a New Generation of T Cell Therapies CATULUS data demonstrate promising initial efficacy in pediatric patients At median follow-up of 8.8 months in pediatric r/r B-ALL patients: ORR was 95.5%; CR was achieved in 90.9% Swimmer plot showing disease assessments in the B-ALL co
Slide 20: MOA and commercial capabilities are key differentiators in AID
Developing and Delivering a New Generation of T Cell Therapies MOA and commercial capabilities are key differentiators in AID Obe-cel is the only CD19 CAR approved in other indications that is now being tested for autoimmune disease Autolus Potential Advantage Favorable tolerability to drive accepta
Slide 21: CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN
Developing and Delivering a New Generation of T Cell Therapies 21 CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN 50 million cell dose selected as recommended Phase 2 dose Patient population: • Patients were significantly impaired with their kidney function and had across the board some
Slide 22: CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS
Developing and Delivering a New Generation of T Cell Therapies CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS Infused adult patients, 50M (n=6) Infused adult patients, 100M (n=3) Any grade, n (%) Grade ≥3, n (%) Any grade, n (%) Grade ≥3, n(%) CRS 3 (50.0) 0 3 (100) 0 ICANS 0 0 0
Slide 23: 5 of 6 patients achieved DORIS with median onset of 5.1 months
Developing and Delivering a New Generation of T Cell Therapies 5 of 6 patients achieved DORIS with median onset of 5.1 months Swimmer plot showing DORIS over time in the 50M adult cohort (n=6) Patient 1 Patient 2 50M adults (n=6) Patient 3 Patient 4 Patient 5 Patient 6 1 2 3 4 5 6 7 8 9 10 11 12 Tim
Slide 24: Clinically meaningful reduction in SLEDAI-2K score observed
Developing and Delivering a New Generation of T Cell Therapies Clinically meaningful reduction in SLEDAI-2K score observed 50M adult cohort (n=6) 100M adult cohort (n=3) Patient 1 Patient 2 Patient 3 Patient 1 Patient 2 30 30 30 30 30 25 25 25 25 25 SLEDAI-2K score SLEDAI-2K score SLEDAI-2K score SL
Slide 25: Lupus nephritis development strategy
Developing and Delivering a New Generation of T Cell Therapies Lupus nephritis development strategy First Approval Label Expansion Leveraging a fast to market strategy CARLYSLE Trial LUMINA Trial Ph3 Randomized Development Rationale Phase 1 Phase 2 Controlled vs SoC • LN is assessed by quantitative
Slide 26: Phase 2 LUMINA trial supports efficient path to market
Developing and Delivering a New Generation of T Cell Therapies Phase 2 LUMINA trial supports efficient path to market Evaluating severe, refractory lupus nephritis (LN) Obe-cel Obe-cel Manufacturing Infusion Monthly safety and L Day-5 Day 1 efficacy follow-up Screening Leukapheresis Lymphodepletion
Slide 27: Refractory lupus nephritis is a high unmet medical need
Developing and Delivering a New Generation of T Cell Therapies Refractory lupus nephritis is a high unmet medical need • Kidneys are one of the most common organs involved in SLE - 30% – 40% are lupus nephritis patients US Treated SLE ∼350,000 • High disease activity is associated with inflammatory
Slide 28: Multiple sclerosis development strategy
Developing and Delivering a New Generation of T Cell Therapies Multiple sclerosis development strategy • Anticipate a Establish Phase 1 Clinical Proof of Concept in MS randomised phase 2/3 study design as 3 x 6 dose escalation design - a higher dose path to approval may be required for CNS effect In
Slide 29: BOBCAT study population represents the highest unmet need in MS
Developing and Delivering a New Generation of T Cell Therapies BOBCAT study population represents the highest unmet need in MS Aspirational – improving disability and moving back on 1. Progressive forms of MS EDSS timeline including all forms of Transformational – halting disease progressive MS with
Slide 30: BOBCAT Phase 1 study design
Developing Next Generation Programmed T Cell Therapies BOBCAT Phase 1 study design Sample size: 12-18 patients infused with obe-cel Dosing: Standard Flu/Cy based preconditioning and a single infusion of 100 or 200 million CART cells and flexibility to adjust dose up or down Primary endpoint: •Safety
Slide 31: Progressive multiple sclerosis is a high unmet medical need
Developing and Delivering a New Generation of T Cell Therapies Progressive multiple sclerosis is a high unmet medical need • MS impacts approximately 1,000,000 individuals in the US1 and there is currently no known cure Obe-cel focus Secondary Progressive MS • Around 30% of patients have progressive
Slide 32: Upcoming milestones
Developing and Delivering a New Generation of T Cell Therapies Upcoming milestones Anticipated Milestone or Catalyst Anticipated Timing Virtual KOL Event Webcast: Spotlight on ALL April 8, 2026 Longer-term follow up data from CARLYSLE trial Year End 2026 Initial clinical data from BOBCAT Phase 1 tri
Slide 33: Building value with obe-cel
Developing and Delivering a New Generation of T Cell Therapies Building value with obe-cel Launch Optimize Expand Strong execution in r/r B-ALL: Leveraging investments: Potential “pipeline in a product" Market leadership • Optimize manufacturing operating new indications: Broad market access / c
Slide 34: Thank you
Thank you Investor Contact: A.Cray@autolus.com Executive Director, Investor Relations & External Communications Autolus.com
Autolus Therapeutics — Investor Presentation (April 2026) on 6ix